Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1728Other hematologic neoplasm 738Plasma cell 354Myeloid 267Dermatologic 173Sarcoma 160Classical hematology 96Breast 96CNS 94Genitourinary 64Gastrointestinal 61Thoracic 45Gynecologic 41Head & Neck 36Other neoplasm 35Other solid neoplasm 5Other 4NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 377Carcinoid Tumor 40Gastro-enteropancreatic neuroendocrine tumor 36Pancreatic Neoplasms 27Carcinoma, Neuroendocrine 27Neoplasms 25Adenoma, Islet Cell 23Neoplasm Metastasis 17Pheochromocytoma 16Paraganglioma 16Stomach Neoplasms 15Neuroblastoma 14Gastrointestinal Neoplasms 14Carcinoma, Hepatocellular 12Thyroid Neoplasms 11Prostatic Neoplasms 11Breast Neoplasms 11Sarcoma 10Esophageal Neoplasms 10Colorectal Neoplasms 10Lung Neoplasms 9Rectal Neoplasms 8Gastrointestinal Stromal Tumors 8Cholangiocarcinoma 8Carcinoma 8Brain Neoplasms 8Anus Neoplasms 8Liver Neoplasms 7Colonic Neoplasms 7Carcinoma, Medullary 7

Interventions

Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma × NET × Clear all
NCT05396118 2024-05-14

Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients

Rigshospitalet, Denmark

Phase 2 Enrolling by invitation
15 enrolled
BreastEndocrineLymphoidNETSarcoma

Breast Neoplasms, Lymphoma, Sarcoma, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡